Wee1 is a novel independent prognostic marker of poor survival in post-chemotherapy ovarian carcinoma effusions

Gynecologic Oncology

Volumn 135, Issue 1, 2014, Pages 118-124

  Slipicevic, Ana ^a   Holth, Arild ^a   Hellesylt, Ellen ^a   Tropé, Claes G ^a,b   Davidson, Ben ^a,b   Flørenes, Vivi Ann ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

Effusions; Ovarian carcinoma; Survival; Tumor progression; Wee1

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CARBOPLATIN; PACLITAXEL; PLATINUM DERIVATIVE; PROTEIN TYROSINE KINASE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; WEE1 LIKE KINASE; CELL CYCLE PROTEIN; NUCLEAR PROTEIN; TUMOR MARKER; WEE1 PROTEIN, HUMAN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CELL LINE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CELL PROLIFERATION ASSAY; CORRELATION ANALYSIS; EFFUSION; FEMALE; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALIGNANT EFFUSION; OVARY CARCINOMA; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; SEROUS OVARIAN CARCINOMA; WESTERN BLOTTING; ASCITES FLUID; BIOSYNTHESIS; CELL CULTURE; MALIGNANT PLEURA EFFUSION; METABOLISM; MIDDLE AGED; MORTALITY; OVARIAN NEOPLASMS; PATHOLOGY; PROGNOSIS; SURVIVAL RATE; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ASCITIC FLUID; CELL CYCLE PROTEINS; CELLS, CULTURED; FEMALE; HUMANS; MIDDLE AGED; NUCLEAR PROTEINS; OVARIAN NEOPLASMS; PLEURAL EFFUSION, MALIGNANT; PROGNOSIS; PROTEIN-TYROSINE KINASES; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84908028769     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2014.07.102     Document Type: Article

References (36)

1. B.T. Hennessy, R.L. Coleman, and M. Markman Ovarian cancer Lancet 374 2009 1371 1382
2. N. Bucher, and C.D. Britten G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer Br J Cancer 98 2008 523 528
3. L.E. Vriend, P.C. De Witt Hamer, C.J. Van Noorden, and T. Würdinger WEE1 inhibition and genomic instability in cancer Biochim Biophys Acta 2013 1836 227 235
4. N. Watanabe, H. Arai, Y. Nishihara, M. Taniguchi, N. Watanabe, and T. Hunter M-phase kinases induce phospho-dependent ubiquitination of somatic Wee1 by SCFbeta-TrCP Proc Natl Acad Sci U S A 101 2004 4419 4424
5. N. Watanabe, H. Arai, J. Iwasaki, M. Shiina, K. Ogata, and T. Hunter Cyclin-dependent kinase (CDK) phosphorylation destabilizes somatic Wee1 via multiple pathways Proc Natl Acad Sci U S A. 102 2005 11663 11668
6. K. Katayama, N. Fujita, and T. Tsuruo Akt/protein kinase B-dependent phosphorylation and inactivation of WEE1Hu promote cell cycle progression at G2/M transition Mol Cell Biol 25 2005 5725 5737
7. C. Li, M. Andrake, R. Dunbrack, and G.H. Enders A bifunctional regulatory element in human somatic Wee1 mediates cyclin A/Cdk2 binding and Crm1-dependent nuclear export Mol Cell Biol 30 2010 116 130
8. S.E. Mir, P.C. De Witt Hamer, P.M. Krawczyk, L. Balaj, A. Claes, and J.M. Niers In silico analysis of kinase expression identifies WEE1 as a gatekeeper against mitotic catastrophe in glioblastoma Cancer Cell 18 2010 244 257
9. J. PosthumaDeBoer, T. Würdinger, H.C. Graat, V.W. van Beusechem, M.N. Helder, and B.J. van Royen WEE1 inhibition sensitizes osteosarcoma to radiotherapy BMC Cancer 11 2011 156
10. G.I. Magnussen, E. Hellesylt, J.M. Nesland, C.G. Trope, V.A. Flørenes, and R. Holm High expression of wee1 is associated with malignancy in vulvar squamous cell carcinoma patients BMC Cancer 13 2013 288
11. H. Wang, M. Huang, D.Y. Zhang, and F. Zhang Global profiling of signaling networks: study of breast cancer stem cells and potential regulation Oncologist 16 2011 966 979
12. G.I. Magnussen, R. Holm, E. Emilsen, A.K. Rosnes, A. Slipicevic, and V.A. Flørenes High expression of Wee1 is associated with poor disease-free survival in malignant melanoma: potential for targeted therapy PLoS One 7 2012 e38254
13. T. Yoshida, S. Tanaka, A. Mogi, Y. Shitara, and H. Kuwano The clinical significance of Cyclin B1 and Wee1 expression in non-small-cell lung cancer Ann Oncol 15 2004 252 256
14. K. Do, J.H. Doroshow, and S. Kummar Wee1 kinase as a target for cancer therapy Cell Cycle 12 2013 3159 3164
15. E. Iorns, C.J. Lord, A. Grigoriadis, S. McDonald, K. Fenwick, and A. Mackay Integrated functional, gene expression and genomic analysis for the identification of cancer targets PLoS One 4 2009 e5120
16. B. Davidson, R. Reich, C.G. Trope', T.L. Wang, and IeM. Shih New determinates of disease progression and outcome in metastatic ovarian carcinoma Histol Histopathol 25 2010 1591 1609
17. B. Davidson Ovarian and primary peritoneal carcinoma Davidson Firat Michael Serous effusions - etiology, diagnosis, prognosis and therapy 2012 Springer London
18. A. Latifi, R.B. Luwor, M. Bilandzic, S. Nazaretian, K. Stenvers, and J. Pyman Isolation and characterization of tumor cells from the ascites of ovarian cancer patients: molecular phenotype of chemoresistant ovarian tumors PLoS One 7 2012 e46858
19. V. Vathipadiekal, D. Saxena, S.C. Mok, P.V. Hauschka, L. Ozbun, and M.J. Birrer Identification of a potential ovarian cancer stem cell gene expression profile from advanced stage papillary serous ovarian cancer PLoS One 7 2012 e29079
20. S. Rizzo, J.M. Hersey, P. Mellor, W. Dai, A. Santos-Silva, and D. Liber Ovarian cancer stem cell-like side populations are enriched following chemotherapy and overexpress EZH2 Mol Cancer Ther 10 2011 325 335
21. E. Meng, B. Long, P. Sullivan, S. McClellan, M.A. Finan, and E. Reed CD44+/CD24- ovarian cancer cells demonstrate cancer stem cell properties and correlate to survival Clin Exp Metastasis 29 2012 939 948
22. L. Hu, C. McArthur, and R.B. Jaffe Ovarian cancer stem-like side-population cells are tumourigenic and chemoresistant Br J Cancer 102 2010 1276 1283
23. T.E. Hetland, D.A. Nymoen, E. Emilsen, J. Kærn, C.G. Tropé, and V.A. Flørenes MGST1 expression in serous ovarian carcinoma differs at various anatomic sites, but is unrelated to chemoresistance or survival Gynecol Oncol 126 2012 460 465
24. J.T. Thigpen, J.A. Blessing, H. Ball, S.J. Hummel, and R.J. Barrett Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study J Clin Oncol 12 1994 1748 1753
25. P. Therasse, S.G. Arbuck, E.A. Eisenhauer, J. Wanders, R.S. Kaplan, and L. Rubinstein New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
26. T.E. Hetland, D.A. Nymoen, A. Holth, K. Brusegard, V.A. Flørenes, and J. Kærn Aurora-B expression in metastatic effusions from advanced-stage ovarian serous carcinoma is predictive of intrinsic chemotherapy resistance Hum Pathol 44 2013 777 785
27. B. Davidson, D.A. Nymoen, C.G. Tropé, J. Kærn, R. Reich, and T.E. Hetland Falkenthal BUB1 mRNA is significantly co-expressed with AURKA and AURKB mRNA in advanced-stage ovarian serous carcinoma Virchows Arch 464 2014 701 707
28. J.R. Guzman, S. Fukuda, and L.M. Pelus Inhibition of caspase-3 by Survivin prevents Wee1 Kinase degradation and promotes cell survival by maintaining phosphorylation of p34Cdc2 Gene Ther Mol Biol 13B 2009 264 273
29. L. Kleinberg, V.A. Flørenes, I. Silins, and K. Haug Trope' CG, Nesland JM, et al Nuclear expression of Survivin is associated with improved survival in metastatic ovarian carcinoma. Cancer 109 2007 228 238
30. A. Sharma, S.V. Madhunapantula, R. Gowda, A. Berg, R.I. Neves, and G.P. Robertson Identification of aurora kinase B and Wee1-like protein kinase as downstream targets of (V600E)B-RAF in melanoma Am J Pathol 182 2013 1151 1162
31. D.S. O'Connor, D. Grossman, J. Plescia, F. Li, H. Zhang, and A. Villa Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin Proc Natl Acad Sci U S A 97 2000 13103 13107
32. H. Beck, V. Nähse, M.S. Larsen, P. Groth, T. Clancy, and M. Lees Regulators of cyclin-dependent kinases are crucial for maintaining genome integrity in S phase J Cell Biol 188 2010 629 638
33. C.S. Sørensen, and R.G. Syljuåsen Safeguarding genome integrity: the checkpoint kinases ATR, CHK1 and WEE1 restrain CDK activity during normal DNA replication Nucleic Acids Res 40 2012 477 486
34. L.M. Pouliot, Y.C. Chen, J. Bai, R. Guha, S.E. Martin, and M.M. Gottesman Cisplatin sensitivity mediated by WEE1 and CHK1 is mediated by miR-155 and the miR-15 family Cancer Res. 72 2012 5945 5955
35. Y. Obi-Ioka, K. Ushijima, M. Kusama, E. Ishikawa-Kobayashi, and A. Fujimura Involvement of Wee1 in the circadian rhythm-dependent intestinal damage induced by docetaxel J Pharmacol Exp Ther 347 2013 242 248
36. P. Indovina, E. Marcelli, D. Di Marzo, N. Casini, I.M. Forte, and F. Giorgi Abrogating G 2/M checkpoint through WEE1 inhibition in combination with chemotherapy as a promising therapeutic approach for mesothelioma Cancer Biol Ther 15 2014 380 388